Gisle Langslet - Researcher Profile | RDL Research Database

Publications

2 shown

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal , Evan A. Stein , Robert Dufour +15 more

2014 The Lancet 730 citations

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson , Michel Farnier , Michel Krempf +13 more

Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there wa...

2015 New England Journal of Medicine 2233 citations

Frequent Co-Authors

Gérald Luc

Maurizio Averna

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo

Researcher Info

h-index: 2
Publications: 2
Citations: 2,963
Institution: Oslo University Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-4034-2243

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.